Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 1Lung Neoplasms 1Lung Diseases 1Esophageal Squamous Cell Carcinoma 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 2Sunitinib 2sitravatinib 1pazopanib 1atezolizumab 1aldesleukin 1Nivolumab 1Nephrectomy 1Metastasectomy 1LY2510924 1Immunoglobulin G 1Cytoreduction Surgical Procedures 1Axitinib 1Ascorbic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Clear-cell metastatic renal cell carcinoma × sitravatinib × Clear all
NCT04904302 2026-03-20

Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
15 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡